Fibrinogen Replacement Therapy for Traumatic Coagulopathy: Does the Fibrinogen Source Matter?

Gael B Morrow, Molly S A Carlier, Sruti Dasgupta, Fiona B Craigen, Nicola J Mutch, Nicola Curry* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
2 Downloads (Pure)


Fibrinogen is the first coagulation protein to reach critically low levels during traumatic haemorrhage. There have been no differential effects on clinical outcomes between the two main sources of fibrinogen replacement: cryoprecipitate and fibrinogen concentrate (Fg-C). However, the constituents of these sources are very different. The aim of this study was to determine whether these give rise to any differences in clot stability that may occur during trauma haemorrhage. Fibrinogen deficient plasma (FDP) was spiked with fibrinogen from cryoprecipitate or Fg-C. A panel of coagulation factors, rotational thromboelastography (ROTEM), thrombin generation (TG), clot lysis and confocal microscopy were performed to measure clot strength and stability. Increasing concentrations of fibrinogen from Fg-C or cryoprecipitate added to FDP strongly correlated with Clauss fibrinogen, demonstrating good recovery of fibrinogen (r2 = 0.99). A marked increase in Factor VIII, XIII and a2-antiplasmin was observed in cryoprecipitate (p < 0.05). Increasing concentrations of fibrinogen from both sources were strongly correlated with ROTEM parameters (r2 = 0.78–0.98). Cryoprecipitate therapy improved TG potential, increased fibrinolytic resistance and formed more homogeneous fibrin clots, compared to Fg-C. In summary, our data indicate that cryoprecipitate may be a superior source of fibrinogen to successfully control bleeding in trauma coagulopathy. However, these different products require evaluation in a clinical setting.
Original languageEnglish
Article number2185
Number of pages15
Journal International Journal of Molecular Sciences
Issue number4
Publication statusPublished - 22 Feb 2021

Bibliographical note

Funding: This work was supported by an NIHR programme grant for applied research; PGfAR01590; “Traumatic coagulopathy and massive transfusion: improving outcomes and saving blood”.


  • Blood Coagulation Disorders/etiology
  • Coagulants/administration & dosage
  • Dose-Response Relationship, Drug
  • Factor VIII/therapeutic use
  • Fibrinogen/administration & dosage
  • Fibrinolysis
  • Hemorrhage/complications
  • Humans
  • Microscopy, Confocal
  • Thrombelastography
  • Thrombin/metabolism
  • Thrombosis/chemically induced
  • fibrinogen
  • cryoprecipitate
  • trauma coagulopathy
  • 2‐antiplasmin/α2‐antiplasmin
  • Factor XIII


Dive into the research topics of 'Fibrinogen Replacement Therapy for Traumatic Coagulopathy: Does the Fibrinogen Source Matter?'. Together they form a unique fingerprint.

Cite this